Research article · 1 Jan 2026
Conference abstractPublished 16 Mar 2015
Efficacy of 6-MP in achieving mucosal healing in children and adolescents with Crohn?s disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: 6-MP is an immunomodulatory medication frequently prescribed for the induction and maintenance of remission in patients with moderately to severely active Crohn?s disease. Although symptomatic improvement has been shown in a proportion of patients with Crohn?s disease taking 6-MP, there is a paucity of data confirming improvement in the degree of mucosal disease in patients receiving this medication. The aim of this study was to determine the degree of endoscopic mucosal healing in a group of pediatric patients treated for Crohn?s disease with 6-MP without the use of a biologic agent. Methods: A retrospective review of the medical records of pediatric patients started on 6-MP for Crohn?s ileitis and/or colitis was performed. The Pediatric Crohn?s disease Activity Index (PCDAI) score and Simple Endoscopic Score for Crohn?s disease (SES-CD) were determined for all subjects at the time they initiated therapy with 6-MP and at least 6 months thereafter. Patients placed on 6-MP as a post-operative prophylactic agent were excluded. Results: Thirteen children ages 8 to 16 years at the time of diagnosis met inclusion criteria. The total daily dosage of 6-MP ranged from 1-1.5 mg/kg (mean=1.1 mg/kg), and the duration of therapy between their initial and surveillance colonoscopies ranged from 2 to 36 months (mean=12.4 months). Seven of the 13 patients (54%) discontinued usage of 6-MP due to perceived failure to respond to treatment. Interestingly, only 4 of these 7 patients experienced an increase in their PCDAI score while taking 6-MP and only 2 of these 7 showed an increase in their SES-CD. Of the 6 patients continued on therapy following their surveillance endoscopic procedures, all experienced an improvement of their PCDAI score, while only 3 patients showed an improvement in their SES-CD. Conclusions: In this small cohort of pediatric patients with moderate or severe Crohn?s disease treated with 6-MP, more than half discontinued therapy within 3 years of treatment. The clinical symptoms and laboratory results that comprise the PCDAI score do not seem to correlate well with the SES-CD score. 6-MP may have been stopped prematurely in some patients.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Gastrointestinal & Digestive System.
Case report · 11 Nov 2025
Bitter Guard: A Gut Wrenching Surprise
Research article · 18 Jun 2025
Ursodeoxycholic Acid Treatment of LPAC Presenting as Post Cholecystectomy Pain: Rationale and Design of a Randomised Trial
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Gastrointestinal & Digestive System
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Cary Qualia”